Maxwell AJ, Hilton B, Clements Ok, Dodwell D, Dulson-Cox J, Kearins O, et al. Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 ladies within the Neglect-Me-Not 2 research. Breast. 2022;61:145–55.
Ryser MD, Weaver DL, Zhao F, Worni M, Grimm LJ, Gulati R, et al. Most cancers Outcomes in DCIS Sufferers With out Locoregional Remedy. J Natl Most cancers Inst. 2019;111:952–60.
Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, et al. Detection of Ductal Carcinoma In Situ in Girls Present process Screening Mammography. JNCI: J Natl Most cancers Inst. 2002;94:1546–54.
Bleyer A, Welch HG. Impact of Three A long time of Screening Mammography on Breast-Most cancers Incidence. N. Engl J Med. 2012;367:1998–2005.
IKNL. NKR Cijfers. Obtainable from: https://iknl.nl/kankersoorten/borstkanker/registratie/incidentie. Accessed on: 07-05-2024
van Seijen M, Lips EH, Thompson AM, Nik-Zainal S, Futreal A, Hwang ES, et al. Ductal carcinoma in situ: to deal with or to not deal with, that’s the query. Br J Most cancers. 2019;121:285–92.
Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast most cancers: ESMO Scientific Observe Pointers for prognosis, remedy and follow-up. Ann Oncol. 2019;30:1194–220.
Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, et al. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Most cancers Inst Monogr 2010;2010:162–77.
Schmitz R, van den Belt-Dusebout AW, Clements Ok, Ren Y, Cresta C, Timbres J, et al. Affiliation of DCIS dimension and margin standing with danger of creating breast most cancers post-treatment: multinational, pooled cohort research. Bmj. 2023;383:e076022.
Tang P, Wang X, Schiffhauer L, Wang J, Bourne P, Yang Q, et al. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers. Ann Clin Lab Sci. 2006;36:16–22.
van Dooijeweert C, van Diest PJ, Willems SM, Kuijpers CCHJ, Overbeek LIH, Deckers IAG. Vital inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide research of 4901 sufferers within the Netherlands. Breast Most cancers Res Deal with. 2019;174:479–88.
Thompson AM, Clements Ok, Cheung S, Pinder SE, Lawrence G, Sawyer E, et al. Administration and 5-year outcomes in 9938 ladies with screen-detected ductal carcinoma in situ: the UK Sloane Mission. Eur J Most cancers. 2018;101:210–9.
Collins LC, Achacoso N, Haque R, Nekhlyudov L, Fletcher SW, Quesenberry CP Jr, et al. Danger components for non-invasive and invasive native recurrence in sufferers with ductal carcinoma in situ. Breast Most cancers Res Deal with. 2013;139:453–60.
Elshof LE, Schaapveld M, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J. Subsequent danger of ipsilateral and contralateral invasive breast most cancers after remedy for ductal carcinoma in situ: incidence and the impact of radiotherapy in a population-based cohort of 10,090 ladies. Breast Most cancers Res Deal with. 2016;159:553–63.
Chua BH, Hyperlink EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, et al. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ within the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, part 3 research. Lancet. 2022;400:431–40.
Luiten JD, Luiten EJT, van der Sangen MJC, Vreuls W, Duijm LEM, Tjan-Heijnen VCG, et al. Patterns of remedy and end result of ductal carcinoma in situ within the Netherlands. Breast Most cancers Res Deal with. 2021;187:245–54.
Mohamed AA, Luo Y, Peng H, Jankowitz RC, Wu S. Understanding Scientific Mammographic Breast Density Evaluation: a Deep Studying Perspective. J Digit Imaging. 2018;31:387–92.
Bonnett M, Wallis T, Rossmann M, Pernick NL, Carolin KA, Segel M, et al. Histologic and Radiographic Evaluation of Ductal Carcinoma In Situ Identified Utilizing Stereotactic Incisional Core Breast Biopsy. Mod Pathol. 2002;15:95–101.
Dahlstrom JE, Sutton S, Jain S Histologic-Radiologic Correlation of Mammographically Detected Microcalcification in Stereotactic Core Biopsies. The American Journal of Surgical Pathology. 1998;22.
Wetstein SC, Stathonikos N, Pluim JPW, Heng YJ, ter Hoeve ND, Vreuls CPH, et al. Deep learning-based grading of ductal carcinoma in situ in breast histopathology photos. Lab Investig. 2021;101:525–33.
Whelan TJ, Pignol J-P, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Lengthy-Time period Outcomes of Hypofractionated Radiation Remedy for Breast Most cancers. N. Engl J Med. 2010;362:513–20.
Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for remedy of early breast most cancers: 10-year follow-up outcomes of two randomised managed trials. Lancet Oncol. 2013;14:1086–94.
Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Ahead): 5-year efficacy and late regular tissue results outcomes from a multicentre, non-inferiority, randomised, part 3 trial. Lancet. 2020;395:1613–26.
Correa C, Harris EE, Leonardi MC, Smith BD, Taghian AG, Thompson AM, et al. Accelerated Partial Breast Irradiation: Government abstract for the replace of an ASTRO Proof-Based mostly Consensus Assertion. Sensible Radiat Oncol. 2017;7:73–9.
Specialisten FM Breast Most cancers – Radiotherapy 2017.
Staff R. RStudio Staff. RStudio: Built-in Improvement Setting for R [Internet]. 2015.
Rakovitch E, Nofech-Mozes S, Narod SA, Hanna W, Thiruchelvam D, Saskin R, et al. Can we choose people with low danger ductal carcinoma in situ (DCIS)? A population-based outcomes evaluation. Breast Most cancers Res Deal with. 2013;138:581–90.
Miller ME, Muhsen S, Olcese C, Patil S, Morrow M, Van Zee KJ. Contralateral Breast Most cancers Danger in Girls with Ductal Carcinoma In Situ: Is it Excessive Sufficient to Justify Bilateral Mastectomy? Ann Surg Oncol. 2017;24:2889–97.
Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, et al. Lengthy-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized scientific trials for DCIS. J Natl Most cancers Inst. 2011;103:478–88.
Donker M, Litière S, Werutsky G, Julien JP, Fentiman IS, Agresti R, et al. Breast-conserving remedy with or with out radiotherapy in ductal carcinoma In Situ: 15-year recurrence charges and end result after a recurrence, from the EORTC 10853 randomized part III trial. J Clin Oncol. 2013;31:4054–9.
Shaaban AM, Hilton B, Clements Ok, Provenzano E, Cheung S, Wallis MG, et al. Pathological options of 11,337 sufferers with major ductal carcinoma in situ (DCIS) and subsequent occasions: outcomes from the UK Sloane Mission. Br J Most cancers. 2021;124:1009–17.
Keymeulen Ok, Geurts SME, Lobbes MBI, Heuts EM, Duijm LEM, Kooreman LFS, et al. Inhabitants-based research of the impact of preoperative breast MRI on the surgical administration of ductal carcinoma in situ. Br J Surg. 2019;106:1488–94.
Anderson C, Winn AN, Dusetzina SB, Nichols HB. Endocrine Remedy Initiation amongst Older Girls with Ductal Carcinoma In Situ. J Most cancers Epidemiol. 2017;2017:6091709.
Chaudhry A, Theodora Ok, Speers C, Olson RA. Prescribing Practices of Endocrine Remedy for Ductal Carcinoma In Situ in British Columbia. Int J Radiat Oncol, Biol, Phys. 2017;99:E39.
Legal guidelines A, Punglia RS. Endocrine Remedy for Major and Secondary Prevention After Prognosis of Excessive-Danger Breast Lesions or Preinvasive Breast Most cancers. J Clin Oncol. 2023;41:3092–9.
Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A, Serrano D, Boni L, Buttiron Webber T, et al. Randomized Placebo Managed Trial of Low-Dose Tamoxifen to Stop Recurrence in Breast Noninvasive Neoplasia: A ten-12 months Comply with-Up of TAM-01 Examine. J Clin Oncol. 2023;41:3116–21.
van Seijen M, Jóźwiak Ok, Pinder SE, Corridor A, Krishnamurthy S, Thomas JS, et al. Variability in grading of ductal carcinoma in situ amongst a world group of pathologists. J Pathol Clin Res. 2021;7:233–42.
Groen EJ, Elshof LE, Visser LL, Rutgers EJT, Winter-Warnars HAO, Lips EH, et al. Discovering the steadiness between over- and under-treatment of ductal carcinoma in situ (DCIS). Breast. 2017;31:274–83.
Kanbayashi C, Thompson AM, Hwang E-SS, Partridge AH, Rea DW, Wesseling J, et al. The worldwide collaboration of lively surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA). J Clin Oncol. 2019;37:TPS603–TPS.
Elshof LE, Tryfonidis Ok, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, et al. Feasibility of a potential, randomised, open-label, worldwide multicentre, part III, non-inferiority trial to evaluate the security of lively surveillance for low danger ductal carcinoma in situ; The LORD research. Eur J Most cancers. 2015;51:1497–510.
Hwang ES, Hyslop T, Lynch T, Frank E, Pinto D, Basila D, et al. The COMET (Comparability of Operative versus Monitoring and Endocrine Remedy) trial: a part III randomised managed scientific trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open. 2019;9:e026797.
Francis A, Thomas J, Fallowfield L, Wallis M, Bartlett JMS, Brookes C, et al. Addressing overtreatment of display detected DCIS; the LORIS trial. Eur J Most cancers. 2015;51:2296–303.
Paszat L, Sutradhar R, Zhou L, Nofech-Mozes S, Rakovitch E. Together with the Ductal Carcinoma-In-Situ (DCIS) Rating within the Improvement of a Multivariable Prediction Mannequin for Recurrence After Excision of DCIS. Clin Breast Most cancers. 2019;19:35–46.
Weinmann S, Leo MC, Francisco M, Jenkins CL, Barry T. Leesman G, et al. Validation of a ductal carcinoma in situ biomarker profile for danger of recurrence after breast-conserving surgical procedure with and with out radio remedy. Clin Most cancers Res. 2020;26:4054–63.
